Decoy Therapeutics Inc. (DCOY) Key Metrics
DCOY valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.8M
- Enterprise value
- $344,923
- P/E (TTM)
- 0.1
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 12.3
- Price / book
- 0.5
- EV / EBITDA
- 1.5
- Dividend yield
- —
- Beta
- 0.64
DCOY key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDCOY returns How much profit the business earns on the capital it uses.
DCOY financial health Debt, liquidity and how easily interest is covered.
DCOY efficiency & capital use Working capital cycle and where the cash goes.
DCOY valuation history
DCOY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DCOY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DCOY cash returned to shareholders
DCOY price vs earnings per share
DCOY key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.8M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$7.0M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −333.8% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −128.7% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.79 | $331.20 | $936.00 | $2,203.20 | $17,856.00 | $32,760.00 | $136,080.00 | $297,000.00 | $999,990.00 | $999,990.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$25.99 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$10.02 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$10.02 | — | — | — | — | — | — | — | — | — |
| Cash per share | $22.24 | — | — | — | — | — | — | — | — | — |
| Book value per share | $12.23 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $12.23 | — | — | — | — | — | — | — | — | — |
| Capex per share | $1.20 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 482K | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −338.3% | −164.0% | −160.1% | −128.7% | −41.9% | −44.9% | −69.8% | −114.2% | −77.9% | −52.1% |
| Return on invested capital (ROIC) | — | — | — | — | −96.3% | −65.2% | −192.1% | — | — | — |
| Return on assets (ROA) | −177.8% | −116.0% | −118.1% | −113.9% | −38.8% | −37.9% | −57.1% | −96.6% | −70.1% | −49.9% |
| Return on tangible assets | −113.2% | −184.4% | −190.4% | −215.7% | −39.9% | −45.8% | −137.9% | −211.0% | −98.6% | −62.5% |
| Free cash flow margin | — | — | — | — | −554.3% | −197.1% | −334.2% | — | — | — |
| Financial health | ||||||||||
| Total debt | — | $221,866 | $289,643 | — | — | $477,028 | $502,332 | — | — | — |
| Cash & short-term investments | $10.7M | $2.4M | $5.9M | $12.1M | $29.2M | $11.1M | $3.7M | $9.8M | $33.3M | $61.1M |
| Net debt | −$10.7M | −$2.2M | −$5.6M | −$12.1M | −$29.2M | −$10.6M | −$3.2M | −$9.8M | −$33.3M | −$61.1M |
| Debt / equity | — | 0.15 | 0.05 | — | — | 0.02 | 0.05 | — | — | — |
| Debt / assets | — | 0.07 | 0.04 | — | — | 0.02 | 0.04 | — | — | — |
| Current ratio | 2.13 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.06 | 5.91 | 16.06 |
| Quick ratio | 2.13 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.02 | 5.83 | 15.94 |
| Working capital | $5.8M | $1.5M | $5.2M | $10.3M | $28.1M | $13.0M | $1.4M | $5.3M | $28.7M | $58.6M |
| Invested capital | −$4.8M | −$700,967 | −$322,985 | −$1.7M | $9.5M | $11.5M | $7.3M | −$546,868 | −$4.2M | −$1.8M |
| Tangible asset value | $5.9M | $1.5M | $5.3M | $10.4M | $29.9M | $13.3M | $1.7M | $9.3M | $29.0M | $59.3M |
| Net current asset value | $5.8M | $1.5M | $5.2M | $10.3M | $28.1M | $13.0M | $1.4M | $9.2M | $28.6M | $58.6M |
| Graham net-net per share | $11.51 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $133,594 | — | — | — |
| Share buybacks (net) | — | — | — | — | — | — | — | $615,014 | — | — |
| Capex / revenue | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 8.9% | 55.3% |
| Capex / depreciation | 80.69 | 0.00 | 0.00 | 224.65 | 0.00 | 0.14 | 0.00 | 0.00 | 0.35 | 2.02 |
| Stock-based compensation / revenue | — | — | — | — | 30.4% | 6.1% | 21.7% | 231.4% | 331.0% | 650.4% |
| R&D / revenue | — | — | — | — | 464.5% | 132.1% | 116.0% | 1,420.8% | 1,333.1% | 2,016.3% |
| SG&A / revenue | — | — | — | — | 331.7% | 116.7% | 222.5% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 268.9 | — | 4.4 | 3.2 | 4.4 |
| Days of inventory on hand | — | — | — | — | — | — | — | 262.2 | 319.2 | 250.1 |
| Days payables outstanding | 40.2 | 63,522.2 | 62,846.1 | 120,302.6 | 32,316.4 | — | — | 994.4 | 1,151.7 | 569.4 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | -727.8 | -829.3 | -314.9 |
| Receivables turnover | — | — | — | 0.00 | — | 1.36 | — | 82.48 | 112.96 | 82.97 |
| Payables turnover | 9.07 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.37 | 0.32 | 0.64 |
| Inventory turnover | — | — | — | — | — | — | — | 1.39 | 1.14 | 1.46 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.27 | 0.29 | 0.04 | 0.03 | 0.01 |
| Average receivables | — | — | — | $1.6M | — | $3.9M | — | $10,162 | $11,283 | $12,181 |
| Average payables | $938,790 | $769,924 | $1.7M | $2.2M | $1.7M | $1.8M | $1.1M | $1.2M | $1.6M | $1.0M |
| Average inventory | — | — | — | — | — | — | — | $309,406 | $443,012 | $454,132 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 21.7% | 35.6% | 63.8% | 0.0% | 0.2% | 0.0% |
Computed from DCOY's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DCOY valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.1. Decoy Therapeutics earned a return on equity of −338.3% in fiscal 2025.
See the DCOY income statement, the DCOY chart for price history, or the DCOY stock overview for the latest quote and news.
DCOY key metrics FAQ
What is Decoy Therapeutics's P/E ratio?
Decoy Therapeutics's trailing P/E ratio is 0.1 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Decoy Therapeutics's return on equity?
Decoy Therapeutics's return on equity (ROE) was −338.3% in fiscal 2025: net income of -$12.5 million on average shareholders' equity of $3.7 million.
What is Decoy Therapeutics's free cash flow yield?
Decoy Therapeutics generated -$4.8 million of free cash flow in fiscal 2025, a free cash flow yield of −128.7% on its market value at year-end ($3.8 million).
What is Decoy Therapeutics's current ratio?
Decoy Therapeutics's current ratio was 2.13 at the end of fiscal 2025: current assets were 2.13 times current liabilities.